P. Casellas

发表

The peripheral benzodiazepine receptor: a promising therapeutic drug target.

S. Galiègue, N. Tinel, P. Casellas, 2003, Current medicinal chemistry.

Involvement of peripheral benzodiazepine receptors in the protection of hematopoietic cells against oxygen radical damage.

P. Casellas, G. Le Fur, D. Dussossoy, 1996, Blood.

Kinetics of Cytotoxicity Induced by Immunotoxins

P. Casellas, P. Gros, B. Bourrié, 1984 .

T-lymphocyte killing by T101-ricin A-chain immunotoxin: pH-dependent potentiation with lysosomotropic amines.

P. Casellas, P. Gros, G. Laurent, 1988, Blood.

Immunohistochemical Assessment of the Peripheral Benzodiazepine Receptor in Breast Cancer and Its Relationship with Survival

Andrew Kramar, Pierre Casellas, S. Galiègue, 2004, Clinical Cancer Research.

SR31747A is a sigma receptor ligand exhibiting antitumoural activity both in vitro and in vivo

S. Galiègue, P. Casellas, P. Carayon, 2003, British Journal of Cancer.

SR31747A: a peripheral &sgr; ligand with potent antitumor activities

S. Galiègue, P. Casellas, B. Bourrié, 2004, Anti-cancer drugs.

σ Receptors in the Immune System: Implications for Potential Therapeutic Intervention - An Overview

S. Galiègue, P. Casellas, H. Vidal, 2007 .

SSR125329A, a high affinity σ receptor ligand with potent anti-inflammatory properties

S. Galiègue, P. Casellas, Corinne J Thomas, 2002 .

Allosteric modulation of peripheral sigma binding sites by a new selective ligand: SR 31747

P. Casellas, G. Fur, J. Breliere, 1994, Journal of Neuroimmunology.

The CB1 receptor antagonist rimonabant reverses the diet‐induced obesity phenotype through the regulation of lipolysis and energy balance

P. Soubrié, S. Galiègue, P. Casellas, 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.

A. Klein-Szanto, P. Casellas, P. Dobrzanski, 2003, Cancer research.

Regulation of 5-hydroxytryptamine2 (5-HT2) receptor expression in cultured rat aortic smooth muscle cells by SR 46349B, a selective 5-HT2 receptor antagonist.

P. Casellas, J. Herbert, M. Rinaldi-Carmona, 1994, The Journal of biological chemistry.

Characterization of NPY receptors controlling lipolysis and leptin secretion in human adipocytes

P. Casellas, J. Maffrand, M. Lafontan, 2000, FEBS letters.

Repression of cell cycle–related proteins by oxaliplatin but not cisplatin in human colon cancer cells

S. Galiègue, P. Casellas, E. Cvitkovic, 2006, Molecular Cancer Therapeutics.

Quantitative method to determine mRNA levels by reverse transcriptase-polymerase chain reaction from leukocyte subsets purified by fluorescence-activated cell sorting: application to peripheral cannabinoid receptors.

P. Casellas, P. Carayon, A. Bord, 1999, Cytometry.

Oligonucleotide Chips for Expression Analysis: Principles and Practical Procedures

S. Galiègue, P. Casellas, A. Péléraux, 2001 .

Transcriptomic classification of antitumor agents: application to the analysis of the antitumoral effect of SR31747A.

S. Galiègue, P. Casellas, H. Vidal, 2003, Gene expression.

Stimulation of peripheral cannabinoid receptor CB2 induces MCP‐1 and IL‐8 gene expression in human promyelocytic cell line HL60

P. Casellas, G. Le Fur, J. Derocq, 1999, FEBS letters.

Treatment of leukemia patients with T101 ricin A chain immunotoxins.

P. Casellas, G. Laurent, A. Frankel, 1988, Cancer treatment and research.

Determination of sensitivity of fresh leukemia cells to immunotoxins.

P. Casellas, G. Laurent, P. Carayon, 1986, Cancer research.

Study of the plasma clearance of antibody--ricin-A-chain immunotoxins. Evidence for specific recognition sites on the A chain that mediate rapid clearance of the immunotoxin.

P. Casellas, F. Jansen, B. Bourrie, 1986, European journal of biochemistry.

High specific cytotoxicity of antibody-toxin hybrid molecules (immunotoxins) for target cells

P. Casellas, P. Gros, B. Pau, 1980 .

Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity

Dominique, P. Casellas, P. Gros, 1982, Immunological reviews.

Effects of therapy with T101 ricin A-chain immunotoxin in two leukemia patients.

P. Casellas, G. Laurent, J. Farcet, 1986, Blood.

Human melanoma cells can be killed in vitro by an immunotoxin specific for melanoma‐associated antigen p97

P. Casellas, J. Brown, P. Gros, 1982, International Journal of Cancer.

Kinetics of cytotoxicity induced by immunotoxins. Enhancement by lysosomotropic amines and carboxylic ionophores.

P. Casellas, P. Gros, F. Jansen, 1984, The Journal of biological chemistry.

Immunotoxin enhancers.

P. Casellas, F. Jansen, 1988, Cancer treatment and research.

Contrasting effects of the protein kinase C inhibitor staurosporine on the interleukin‐1 and phorbol ester activation pathways in the EL4–6.1 thymoma cell line

P. Casellas, A. D. d'Angeac, D. Shire, 1992, Journal of cellular physiology.

In vivo effects of a new immunosuppressive sigma ligand, SR 31747, on mouse thymus.

P. Casellas, G. Le Fur, P. Carayon, 1996, Immunopharmacology and immunotoxicology.

The sigma ligand SR 31747 prevents the development of acute graft-versus-host disease in mice by blocking IFN-gamma and GM-CSF mRNA expression.

P. Casellas, G. Le Fur, P. Carayon, 1995, International journal of immunopharmacology.

Immunopharmacological profile of SR 31747: In vitro and in vivo studies on humoral and cellular responses

P. Casellas, G. Fur, J. Breliere, 1994, Journal of Neuroimmunology.

Neutralization of adrenomedullin inhibits the growth of human glioblastoma cell lines in vitro and suppresses tumor xenograft growth in vivo.

N. Brünner, P. Casellas, O. Chinot, 2002, The American journal of pathology.

Interleukin‐13 stimulates interleukin‐6 production by human keratinocytes

P. Casellas, A. Minty, P. Ferrara, 1994, FEBS letters.

Up-regulation of 5-HT2 receptors in the rat brain by repeated administration of SR 46349B, a selective 5-HT2 receptor antagonist.

J. Simiand, P. Soubrié, P. Casellas, 1993, European journal of pharmacology.

Development of a radioimmunoassay for SR 31747A, a new sigma ligand, in human plasma.

P. Casellas, D. Dussossoy, G. Pastor, 1996, Journal of pharmaceutical and biomedical analysis.

Purification and Characterization of the Human SR 31747A-binding Protein

S. Galiègue, P. Casellas, P. Ferrara, 1997, The Journal of Biological Chemistry.

Development of a monoclonal antibody to immuno-cytochemical analysis of the cellular localization of the peripheral benzodiazepine receptor.

P. Casellas, D. Dussossoy, P. Carayon, 1996, Cytometry.

Internalization and intracellular fate of anti-CD5 monoclonal antibody and anti-CD5 ricin A-chain immunotoxin in human leukemic T cells.

P. Casellas, S. Ravel, M. Colombatti, 1992, Blood.

Colocalization of sterol isomerase and sigma(1) receptor at endoplasmic reticulum and nuclear envelope level.

P. Casellas, D. Dussossoy, G. Loison, 1999, European journal of biochemistry.

CB2, a paradigm for a novel class of “onco-GPCRs”?

P. Casellas, 2004 .

Effects of therapy with T101 ricin A-chain immunotoxin in two leukemia patients.

P. Casellas, G. Laurent, J. Farcet, 1986, Blood.

A DNA microarray-based approach to elucidate the effects of the immunosuppressant SR31747A on gene expression in Saccharomyces cerevisiae.

S. Galiègue, P. Casellas, S. Silve, 2002, Gene expression.

Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1.

P. Casellas, M. Rinaldi-Carmona, B. Calandra, 1995, The Biochemical journal.

Cannabinoid-receptor expression in human leukocytes.

P. Casellas, G. Fur, D. Shire, 1993, European journal of biochemistry.

Effect of a new, potent, non-peptide V1a vasopressin antagonist, SR 49059, on the binding and the mitogenic activity of vasopressin on Swiss 3T3 cells.

P. Casellas, G. Le Fur, C. Serradeil-Le Gal, 1994, Biochemical pharmacology.

SR 144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist.

P. Casellas, G. Fur, M. Rinaldi-Carmona, 1999, The Journal of pharmacology and experimental therapeutics.

Optimal elimination of leukemic T cells from human bone marrow with T101-ricin A-chain immunotoxin.

P. Casellas, G. Laurent, O. Gros, 1985, Blood.

Toxin selection and modification: utilization of the A chain of ricin.

P. Casellas, P. Gros, O. Gros, 1988, Cancer treatment and research.

Significance of the Kinetics of Immunotoxin Cytotoxicity

P. Casellas, O. Gros, D. Dussossoy, 1984 .

High Efficiency of Immunotoxin Potentiated by Lysosomotropic Amines to Specifically Kill Tumor Cells

P. Casellas, P. Gros, F. Jansen, 1983 .

Specific Killing of Human and Mouse Tumor Cells by Immunotoxins

P. Casellas, P. Gros, O. Gros, 1982 .

Immunotoxins: hybrid molecules of monoclonal antibodies and a toxin subunit specifically kill tumour cells

P. Casellas, P. Gros, B. Pau, 1981, Nature.

In vivo cytotoxic efficacy of immunotoxins prepared from anti-CD5 antibody linked to ricin A-chain

P. Casellas, O. Rostaing-Capaillon, Odile Rostaing-Capaillon, 2005, Cancer Immunology, Immunotherapy.

Parameters affecting tumor-specific delivery of anti-CD5 antibody-ricin A chain immunotoxins in vivo.

P. Casellas, O. Rostaing-Capaillon, Pierre Casellas, 1990, Cancer research.

An anti‐CD5 immunotoxin for chronic lymphocytic leukemia: Enhancement of cytotoxicity with human serum albumin‐monensin

P. Casellas, M. Borowitz, A. Frankel, 1989, International journal of cancer.

REPLACEMENT OF THE B CHAIN OF RICIN WITH SPECIFIC CONVENTIONAL OR MONOCLONAL ANTIBODIES

P. Casellas, P. Gros, B. Pau, 1981 .

The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor‐independent pathway in hematopoietic cell lines

P. Casellas, M. Rinaldi-Carmona, J. Derocq, 1998, FEBS letters.

A sigma ligand, SR 31747A, potently modulates Staphylococcal enterotoxin B‐induced cytokine production in mice

P. Casellas, G. Le Fur, B. Bourrie, 1996, Immunology.

Enhancement of endotoxin‐induced interleukin‐10 production by SR 31747A, a sigma ligand

P. Casellas, G. Le Fur, B. Bourrié, 1995, European journal of immunology.

Cannabinoid receptor CB1 activates the Na+/H+ exchanger NHE‐1 isoform via Gi‐mediated mitogen activated protein kinase signaling transduction pathways

P. Casellas, J. Pouysségur, F. McKenzie, 1999, FEBS letters.

Subversion and Utilization of the Host Cell Cyclic Adenosine 5′-Monophosphate/Protein Kinase A Pathway by Brucella During Macrophage Infection1

P. Casellas, J. Liautard, A. Gross, 2003, The Journal of Immunology.

Macrophage Infection During Brucella Kinase A Pathway by-Monophosphate / Protein ′ Cyclic Adenosine 5 Subversion and Utilization of the Host Cell

P. Casellas, J. Liautard, A. Gross, 2003 .

Effect of substance P on cytokine production by human astrocytic cells and blood mononuclear cells: characterization of novel tachykinin receptor antagonists

P. Casellas, J. Breliere, G. Le Fur, 1996 .

A beneficial aspect of a CB1 cannabinoid receptor antagonist: SR141716A is a potent inhibitor of macrophage infection by the intracellular pathogen Brucella suis

P. Casellas, J. Liautard, S. Ouahrani-Bettache, 2000, Journal of leukocyte biology.

Regulation of peripheral cannabinoid receptor CB2 phosphorylation by the inverse agonist SR 144528. Implications for receptor biological responses.

P. Casellas, D. Dussossoy, M. Bouaboula, 1999, The Journal of biological chemistry.

Cannabinoids enhance human B‐cell growth at low nanomolar concentrations

P. Casellas, G. Le Fur, J. Derocq, 1995, FEBS letters.

International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors

M. Herkenham, F. Barth, M. Herkenham, 2002, Pharmacological Reviews.

Characterization of two cloned human CB1 cannabinoid receptor isoforms.

P. Casellas, P. Ferrara, M. Rinaldi-Carmona, 1996, The Journal of pharmacology and experimental therapeutics.

Subcellular localization of peripheral benzodiazepine receptors on human leukocytes.

P. Casellas, G. Le Fur, P. Carayon, 1994, Laboratory investigation; a journal of technical methods and pathology.

A Selective Inverse Agonist for Central Cannabinoid Receptor Inhibits Mitogen-activated Protein Kinase Activation Stimulated by Insulin or Insulin-like Growth Factor 1

P. Casellas, J. Maffrand, M. Rinaldi-Carmona, 1997, The Journal of Biological Chemistry.

Endocytosis of an antibody ricin A-chain conjugate (immuno-A-toxin) adsorbed on colloidal gold. Effects of ammonium chloride and monensin.

P. Casellas, P. Gros, F. Jansen, 1985, Experimental cell research.

The neuroprotective agent SR 57746A abrogates experimental autoimmune encephalomyelitis and impairs associated blood-brain barrier disruption: implications for multiple sclerosis treatment.

P. Casellas, J. Maffrand, B. Bourrie, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Internalization of the cytotoxic molecules of T101 F(ab')2-(ricin-A-chain) immunotoxin into human T-leukemic cells.

P. Casellas, S. Ravel, 1990, European journal of biochemistry.

Protein methylation in animal cells. II. Inhibition of S-adenosyl-L-methionine:protein(arginine) N-methyltransferase by analogs of S-adenosyl-L-homocysteine.

P. Casellas, P. Jeanteur, 1978, Biochimica et biophysica acta.

Cannabinoid receptor CB1 mRNA is highly expressed in the rat ciliary body: implications for the antiglaucoma properties of marihuana.

P. Casellas, G. Gessa, A. Porcella, 1998, Brain research. Molecular brain research.

Interactive report Cannabinoid receptor CB mRNA is highly expressed in the rat ciliary

P. Casellas, G. Gessa, A. Porcella, 1998 .

Peripheral benzodiazepine receptor modulation with phagocyte differentiation.

P. Casellas, P. Carayon, X. Canat, 1993, Biochemical pharmacology.

Prolonged elevation of intracellular cyclic AMP levels in U937 cells increases the number of receptors for and the responses to formylmethionyl-leucylphenylalanine, independently of the differentiation process.

P. Casellas, R. Zumbihl, B. Rouot, 1995, The Biochemical journal.

Techniques for Ex-Vivo Bone Marrow Treatment with Immunotoxins

P. Casellas, G. Laurent, F. Jansen, 1988 .

Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations.

S. Galiègue, P. Casellas, G. Fur, 1995, European journal of biochemistry.

Standardization of mRNA titration using a polymerase chain reaction method involving co-amplification with a multispecific internal control.

P. Casellas, X. Dumont, D. Shire, 1992, The Journal of biological chemistry.

Trichokirin, a ribosome-inactivating protein from the seeds of Trichosanthes kirilowii Maximowicz. Purification, partial characterization and use for preparation of immunotoxins.

L. Barbieri, A. Bolognesi, F. Stirpe, 1988, European journal of biochemistry.

Activation of mitogen-activated protein kinase couples neurotensin receptor stimulation to induction of the primary response gene Krox-24.

P. Casellas, D. Gully, J. Monroe, 1996, The Biochemical journal.

Identification and pharmacological characterization of SRBP-2: a novel SR31747A-binding protein.

S. Galiègue, P. Casellas, A. Kramar, 2003, Cancer research.

lnterleukin-13 is a new human lymphokine regulating inflammatory and immune responses

P. Casellas, M. Kaghad, A. Minty, 1993, Nature.

Neurotensin is an antagonist of the human neurotensin NT2 receptor expressed in Chinese hamster ovary cells.

P Ferrara, P. Soubrié, P. Casellas, 1998, European journal of pharmacology.

Expression of the peripheral benzodiazepine receptor triggers thymocyte differentiation.

S. Galiègue, N. Tinel, P. Casellas, 2004, Gene expression.

Cloning and Characterization of PRAX-1

S. Galiègue, P. Casellas, G. Le Fur, 1999, The Journal of Biological Chemistry.

Peripheral benzodiazepine receptors and mitochondrial function

S. Galiègue, P. Casellas, A. Basile, 2002, Neurochemistry International.

SAR103168: a tyrosine kinase inhibitor with therapeutic potential in myeloid leukemias

A. Zilberstein, P. Casellas, M. Levit, 2013, Leukemia & lymphoma.

Immunocytochemical assessment of sigma-1 receptor and human sterol isomerase in breast cancer and their relationship with a series of prognostic factors

P. Casellas, A. Kramar, S. Gourgou, 2000, British Journal of Cancer.

Studies on components of immunotoxins: Purification of ricin and its subunits and influence of unreacted antibodies

P. Casellas, P. Gros, F. Jansen, 1985, International journal of cancer.

Evidence for absence of toxicity of T101 immunotoxin on human hematopoietic progenitor cells prior to bone marrow transplantation.

P. Casellas, L. Douay, F. Jansen, 1985, Cancer research.

Comparison of the cytotoxic potency of T101 Fab, F(ab')2 and whole IgG immunotoxins.

P. Casellas, G. Laurent, S. Ravel, 1988, Journal of immunology.

RATIONALE FOR THE SELECTION OF RICIN A‐CHAIN ANTI‐T IMMUNOTOXINS FOR MATURE T CELL DEPLETION

P. Casellas, G. Laurent, F. Jansen, 1987, Transplantation.

Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression.

P. Casellas, M. Rinaldi-Carmona, B. Calandra, 1996, European journal of biochemistry.

Both the Immunosuppressant SR31747 and the Antiestrogen Tamoxifen Bind to an Emopamil-Insensitive Site of Mammalian Δ8-Δ7 Sterol Isomerase

Pascual Ferrara, Raymond Paul, Pierre Casellas, 1998 .

Distribution profile and properties of peripheral-type benzodiazepine receptors on human hemopoietic cells.

P. Casellas, D. Shire, G. Le Fur, 1993, Life sciences.

Echinomycin Suppresses the Pyrogenic Effects of Endotoxin and Interleukin- lβ in Human Endothelial Cells and Peripheral Blood Mononuclear Cells

P. Casellas, J. Herbert, J. Derocq, 1996, Thrombosis and Haemostasis.

Cannabinoid receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

Stephen P. H. Alexander, M. Herkenham, K. Mackie, 2019, IUPHAR/BPS Guide to Pharmacology CITE.

Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528.

P. Casellas, P. Ferrara, M. Rinaldi-Carmona, 1999, Life sciences.

Mutation Analysis in the Coding Sequence of Thymidine Kinase 1 in Breast and Colorectal Cancer

S. Galiègue, P. Casellas, S. Romain, 2003 .

Mutation analysis in the coding sequence of thymidine kinase 1 in breast and colorectal cancer.

S. Galiègue, P. Casellas, S. Romain, 2003, The International journal of biological markers.

Involvement of the peripheral benzodiazepine receptor in the development of rheumatoid arthritis in Mrl/lpr mice.

S. Galiègue, P. Casellas, H. Vidal, 2002, European journal of pharmacology.

Ligands of the peripheral benzodiazepine receptor have therapeutic effects in pneumopathies in vivo.

P. Casellas, E. Bribes, B. Bourrié, 2003, Immunology letters.

SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.

P. Casellas, G. Fur, M. Rinaldi-Carmona, 1998, The Journal of pharmacology and experimental therapeutics.

Hypersensitization of the Orexin 1 Receptor by the CB1 Receptor

Pierre Casellas, P. Casellas, G. Le Fur, 2003, Journal of Biological Chemistry.

Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation.

P. Casellas, L. Fajas, G. Le Fur, 2005, European journal of pharmacology.

Modulation of CB1 cannabinoid receptor functions after a long-term exposure to agonist or inverse agonist in the Chinese hamster ovary cell expression system.

P. Casellas, G. Fur, M. Rinaldi-Carmona, 1998, The Journal of pharmacology and experimental therapeutics.

Stimulation of Cannabinoid Receptor CB1 Induces krox-24 Expression in Human Astrocytoma Cells (*)

P. Casellas, G. Fur, M. Rinaldi-Carmona, 1995, The Journal of Biological Chemistry.

Modulation and functional involvement of CB2 peripheral cannabinoid receptors during B-cell differentiation.

S. Galiègue, P. Casellas, G. Fur, 1998, Blood.

Genomic and Functional Changes Induced by the Activation of the Peripheral Cannabinoid Receptor CB2 in the Promyelocytic Cells HL-60

P. Casellas, J. Derocq, O. Jbilo, 2000, The Journal of Biological Chemistry.

Gi protein modulation induced by a selective inverse agonist for the peripheral cannabinoid receptor CB2: implication for intracellular signalization cross-regulation.

P. Casellas, P. Carayon, M. Bouaboula, 1999, Molecular pharmacology.

Expression pattern of sigma receptor 1 mRNA and protein in mammalian retina.

P. Casellas, V. Ganapathy, N. Agarwal, 2001, Brain research. Molecular brain research.

Expression pattern of the type 1 sigma receptor in the brain and identity of critical anionic amino acid residues in the ligand-binding domain of the receptor.

P. Casellas, V. Ganapathy, P. Seth, 2001, Biochimica et biophysica acta.

Regulation of Peripheral Cannabinoid Receptor CB2Phosphorylation by the Inverse Agonist SR 144528

P. Casellas, D. Dussossoy, M. Bouaboula, 1999, The Journal of Biological Chemistry.

In vivo inhibition of endotoxin-induced pro-inflammatory cytokines production by the sigma ligand SR 31747.

P. Casellas, G. Le Fur, B. Bourrie, 1995, The Journal of pharmacology and experimental therapeutics.

Monitoring Cellular Responses to Listeria monocytogenes with Oligonucleotide Arrays*

Pierre Casellas, S. Galiègue, P. Casellas, 2000, The Journal of Biological Chemistry.

Transient protection by peripheral benzodiazepine receptors during the early events of ultraviolet light-induced apoptosis

P. Casellas, P. Cuq, T. Lavabre‐Bertrand, 2001, Cell Death and Differentiation.

Involvement of the peripheral benzodiazepine receptor in the development of cutaneous pathology in Mrl/Lpr mice.

S. Galiègue, P. Casellas, E. Bribes, 2003, Immunology letters.

Peripheral benzodiazepine receptor mapping in rat kidney. Effects of angiotensin II-induced hypertension.

P. Casellas, D. Casellas, D. Dussossoy, 2002, Journal of the American Society of Nephrology : JASN.

Sigma receptor ligands: applications in inflammation and oncology.

P. Casellas, J. Derocq, H. Vidal, 2004, Current opinion in investigational drugs.

Cannabinoid receptors in GtoPdb v.2023.1

Stephen P. H. Alexander, M. Herkenham, K. Mackie, 2023, IUPHAR/BPS Guide to Pharmacology CITE.

Effect of substance P on cytokine production by human astrocytic cells and blood mononuclear cells: characterization of novel tachykinin receptor antagonists

P. Casellas, J. Breliere, G. Le Fur, 1996, FEBS letters.

Recent advances with immunotoxins

P. Casellas, G. Laurent, F. Jansen, 1985 .

[Exploitation of expression profiles: examples in oncology].

S. Galiègue, P. Casellas, 2002, Journal de la Societe de biologie.

Expression profile and up-regulation of PRAX-1 mRNA by antidepressant treatment in the rat brain.

P. Soubrié, S. Galiègue, P. Casellas, 2002, Molecular pharmacology.

Transcriptome response of enterocytes to dietary lipids: impact on cell architecture, signaling, and metabolism genes.

P. Casellas, M. Rousset, J. Chambaz, 2008, American journal of physiology. Gastrointestinal and liver physiology.

Immunohistochemical Assessment of the Peripheral Benzodiazepine Receptor in Human Tissues

S. Galiègue, P. Casellas, E. Bribes, 2004, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

SSR125329A, a high affinity sigma receptor ligand with potent anti-inflammatory properties.

S. Galiègue, P. Casellas, Corinne J Thomas, 2002, European journal of pharmacology.

Monitoring Cellular Responses to Listeria monocytogenes with Oligonucleotide Arrays*

S. Galiègue, P. Casellas, V. Baron, 2000, The Journal of Biological Chemistry.

Protein methylation in animal cells. I. Purification and properties of S-adenosyl-L-methionine:protein (arginine) N-methyltransferase from Krebs II ascites cells.

P. Casellas, P. Jeanteur, 1978, Biochimica et biophysica acta.

International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors

M. Herkenham, K. Mackie, T. Bonner, 2002, Pharmacological Reviews.

Techniques for Characterization of Leucocyte Antigens and Utilization of Antibodies in Therapy

H. Tanke, J. Ploem, K. Lennert, 1984 .

Immunotoxins in Cancer Therapy

P. Casellas, P. Gros, G. Laurent, 1988 .